156. Safety of Remibrutinib across Immune-mediated Diseases Supports Development in Multiple Sclerosis
Kieseier B, Montalban X, Williams M, Airas L, Saini S, Hide M, Sussman G, Nakahara J, Bermel R, Dörner T, Loop B, DeLasHeras V, Willi R, Haemmerle S, Zharkov A, Barbier N, Azmon A, Siegel R, Cenni B, Haddad I, Wiendl H, Maurer M, Giménez-Arnau A, Chitnis T. 156. Safety of Remibrutinib across Immune-mediated Diseases Supports Development in Multiple Sclerosis. Multiple Sclerosis And Related Disorders 2024, 92: 106117. DOI: 10.1016/j.msard.2024.106117.Peer-Reviewed Original ResearchAdverse eventsSafety profileOral Bruton's tyrosine kinase inhibitorTreatment of relapsing multiple sclerosisBruton tyrosine kinase inhibitorSkin/subcutaneous tissue disordersUpper respiratory tract infectionMultiple sclerosisTyrosine kinase inhibitorsPhase 3 trialRespiratory tract infectionsGrouped adverse eventsIntegrated safety analysisNervous system disordersTreatment discontinuationTract infectionsRemibrutinibTissue disordersKinase inhibitorsSystem disordersOff-target effectsGastrointestinal disordersDoseInfectionPooled dataA review of Bruton’s tyrosine kinase inhibitors in multiple sclerosis
Airas L, Bermel R, Chitnis T, Hartung H, Nakahara J, Stuve O, Williams M, Kieseier B, Wiendl H. A review of Bruton’s tyrosine kinase inhibitors in multiple sclerosis. Therapeutic Advances In Neurological Disorders 2024, 17: 17562864241233041. PMID: 38638671, PMCID: PMC11025433, DOI: 10.1177/17562864241233041.Peer-Reviewed Original ResearchBruton tyrosine kinase inhibitorChronic spontaneous urticariaFirst-generation BTK inhibitorSystemic lupus erythematosusBruton's tyrosine kinaseTyrosine kinase inhibitorsMS disease-modifying treatmentsBTK inhibitorsDisease-modifying treatmentsSafety profileB cellsMultiple sclerosisChronic useRheumatoid arthritisSecond-generation BTK inhibitorsB cell depletion therapyTreatment of B-cell malignanciesB-cell modulationDiverse autoimmune conditionsPhase II trialGadolinium-enhancing lesionsB-cell malignanciesMagnetic resonance imaging scansLong-term administrationFemale reproductive health
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply